|  |  |  |  | Univariate | Multivariate | ||
---|---|---|---|---|---|---|---|---|
 |  |  | N | 25(OH)D <25 nmol/L, N (%) | OR (95 % CI) | P | Adjusted OR (95 % CI)a | P |
Phenotypic characteristics | Sex | Male | 120 | 49 (41Â %) | Ref | Â | Ref | Â |
 | Female | 140 | 91 (65 %) | 2.67 (1.62 to 2.45) | <0.001 | 2.60(1.50 to 4.52) | 0.001 | |
Season of recruitment | Summer | 137 | 66 (48Â %) | Ref | Â | Ref | Â | |
 | Winter | 123 | 74 (60 %) | 1.62 (0.99 to 2.65) | 0.053 | 1.75 (1.00 to 3.04) | 0.047 | |
Socioeconomic statusb | Lower | 177 | 96 (54Â %) | Ref | Â | Â | Â | |
 | Higher | 83 | 44 (53 %) | 0.95 (0.56 to 1.60) | 0.85 | - | - | |
Extent of disease | Unilateral | 144 | 67 (46Â %) | Ref | Â | Ref | Â | |
 | Bilateral | 116 | 73 (63 %) | 1.95 (1.18 to 3.21) | 0.009 | 1.89 (1.49 to 4.52) | 0.025 | |
Sputum smear | 1–99 AFB per 100 HPF | 106 | 53 (50 %) | Ref |  |  |  | |
 | ≥100 AFB per 100 HPF | 154 | 87 (56 %) | 0.74 (0.45 to 1.22) | 0.24 | - | - | |
Age | <30Â years | 124 | 67 (54Â %) | Ref | Â | Â | Â | |
 | ≥30 years | 136 | 73 (54 %) | 0.98 (0.60 to 1.60) | 0.95 | - | - | |
Genotypic characteristics | rs731236, VDR | AA | 83 | 38 (46Â %) | Ref | 0.14 | Â | Â |
 | AG | 115 | 67 (58 %) | 1.65 (0.93 to 2.92) |  | - | - | |
 | GG | 27 | 17 (63 %) | 2.01 (0.82 to 4.91) |  | - | - | |
rs1544410,VDR | CC | 53 | 23 (43Â %) | Ref | 0.098 | Â | Â | |
 | CT | 128 | 74 (58 %) | 1.78 (0.94 to 3.41) |  | 1.66 (0.84 to 3.28) | 0.14 | |
 | TT | 54 | 34 (63 %) | 2.21 (1.02 to 4.81) |  | 2.23 (0.98 to 5.05) | 0.054 | |
rs2228570,VDR | GG | 137 | 76 (55Â %) | Ref | 0.96 | Â | Â | |
 | GA | 83 | 47 (57 %) | 1.04 (0.60 to 1.81) |  | - | - | |
 | AA | 15 | 8 (53 %) | 0.92 (0.31 to 2.67) |  | - | - | |
rs2060793, CYP2R1 | GG | 112 | 62 (55Â %) | Ref | 0.81 | Â | Â | |
 | AG | 106 | 62 (58 %) | 0.80 (0.22 to 2.94) |  | - | - | |
 | AA | 10 | 5 (50 %) | 1.13 (0.66 to 1.94) |  | - | - | |
rs10500804, CYP2R1 | GG | 59 | 34 (58Â %) | Ref | 0.34 | Â | Â | |
 | GT | 120 | 69 (58 %) | 0.99 (0.53 to 1.87) |  | - | - | |
 | TT | 52 | 24 (46 %) | 0.63 (0.29 to 1.33) |  | - | - | |
rs10766197, CYP2R1 | AA | 52 | 29 (56Â %) | Ref | 0.60 | Â | Â | |
 | AG | 124 | 72 (58 %) | 1.18 (0.57 to 2.11) |  | - | - | |
 | GG | 56 | 28 (50 %) | 0.84 (0.37 to 1.72) |  | - | - | |
rs7041, DBP | AA | 55 | 34 (62Â %) | Ref | 0.57 | Â | Â | |
 | AC | 106 | 57 (54 %) | 0.72 (0.37 to 1.47) |  | - | - | |
 | CC | 71 | 38 (54 %) | 0.71 (0.34 to 1.45) |  | - | - | |
rs4588,DBP | GG | 122 | 66 (54Â %) | Ref | 0.14 | Â | Â | |
 | GT | 91 | 49 (54 %) | 0.99 (0.57 to 1.70) |  | - | - | |
 | TT | 21 | 16 (76 %) | 2.71 (0.93 to 7.88) |  | - | - |